Escherichia Coli Infections Clinical Trial
Official title:
Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals
Verified date | March 2024 |
Source | Suez Canal University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This descriptive cross-sectional study will beconducted in Suez Canal University Hospitals (SCUHs) in Ismailia, Egypt. The study aims to detect Escherichia coli biofilm producers to improve prognosis and treatment and reduce morbidity and mortality rates due to this infection.
Status | Completed |
Enrollment | 47 |
Est. completion date | February 20, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients showing criteria for Symptomatic Urinary Tract Infection (SUTI) according to Center of Diseases and Control criteria (CDC) (CDC, 2022). Patient has at least one of the following signs or symptoms: - fever (>38.0°C) - suprapubic tenderness - costovertebral angle pain or tenderness - urinary urgency - urinary frequency - dysuria Exclusion Criteria: - 1. Patients received antibiotic treatment in the last 48 hours 2. Refusal of the patients to participate in the study |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Medicine, Suez canal university | Ismailia |
Lead Sponsor | Collaborator |
---|---|
Suez Canal University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | antibiotic resistance | Susceptibility testing will be performed according to the standard Kirby-Bauer disk diffusion method on Mueller Hinton agar and interpreted according to the Clinical and Laboratory Standard Institute (CLSI) guidelines. Antibiotic discs include Amoxicillin-clavulanate, Piperacillin-tazobactam, Cefotaxime, Ceftazidime, Aztreonam, Imipenem, Gentamicin, Amikacin, Norfloxacin, ciprofloxacin, levofloxacin, Trimethoprim-sulfamethoxazole, Nitrofurantoin. | from 18-24 hours | |
Primary | Congo red Agar method (CRA) | The medium will be prepared by adding 37 gm brain heart infusion (BHI) powder, 50 gm sucrose and 10 gm agar to 900 ml distilled water and autoclaved at 121°C for 15 minutes. Congo red will be prepared separately by dissolving 0.8 gm of congo red stain in 100 ml distilled water as concentrated aqueous solution and autoclaved at 121°C for 15 minutes and thenit will be added to the previous media when it cooled to 55°C. The congo red agar will be distributed in sterile plates. Plates will be inoculated by the test bacteria and incubated aerobically for 24 to 48 hours at 37°C. Positive results will be indicated by black colonies with a dry crystalline consistency. Weak slime producers usually remain pink. | 24 to 48 hours | |
Primary | Modified tissue culture plate method (MTCP) | All isolates will be screened for their ability to form biofilm by the TCP method with a modification in duration of incubation, which will be extended to 24 hours and the addition of glucose. | up to 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
Completed |
NCT03303937 -
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
|
N/A | |
Not yet recruiting |
NCT03869593 -
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
|
||
Completed |
NCT02853708 -
Epidemiology of ST131 in Besançon University Hospital
|
N/A | |
Active, not recruiting |
NCT02729116 -
Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01324726 -
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
|
N/A | |
Completed |
NCT01406288 -
Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
|
N/A | |
Not yet recruiting |
NCT03800147 -
Effects of Nutritional Fat on the Growth of Intestinal E. Coli
|
N/A | |
Completed |
NCT00167986 -
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
|
Phase 4 | |
Terminated |
NCT00362869 -
Enteroaggregative E.Coli (EAEC)
|
Phase 1 | |
Completed |
NCT00167999 -
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
|
Phase 4 |